Newsletter

INOL is Genetically Engineered for Gains

Good Evening Fellow Traders,

DNA testing has been a speeding train roaring towards us for quite some time.

That train has arrived and with it comes an unprecedented chance for companies to deliver sophisticated and in-demand products worth BLNS each year.

The numbers themselves are a dream:

The DNA test kit manufacturing market size for instance generated more than $2B in 2012 and the growth between 2007 and 2012 was a whopping 18.1%.

And that’s just small segment in this exploding industry – forensic DNA testing is a $10.1Bmarket set to reach $17B by 2016.

This dynamic and clearly lucrative industry is brimming and provides an entry for investors.

INOL is our exclusive ticket to unlock some of this gain and be part of the revolution unfolding right before all our eyes.

INOL has exploded onto the scene, just in time to take a slice from this Multi-BLNS pie, and you now have a chance to benefit from it.

INOL has placed itself well in a winning industry, now it’s your turn to reward its excellent choice.

InoLife Technologies Inc. (INOL)

Highlights

·      INOL is pioneering the development of medical DNA testing technologies that will help save lives

·      INOL markets a viable DNA testing solution for Plavix (clopidogrel), a leading screening medication which helps prevent heart attacks and strokes

·      INOL has seen increased interest in recent trading with volume exploding 2,341.17PCT

·      INOL’s recent appointment of Nick Plessas as V.P. of Business Development marks an interesting strategic step as the company pushes to expand market reach and increase revenues.

About INOL

INOL (InoLife Technologies Inc.) is a development stage company which engages in the identification, manufacture, and marketing of healthcare products and services.

INOL was established in order to identify and develop a wide variety of Human and Veterinary Healthcare technology, product and service solutions. Solutions are designed to include strategic services, product integration, system implementations and innovative solutions to enable state-of-the-art healthcare for today and the future.

INOL offers DNA testing products for Plavix; and pre-disposition screening for various genetic diseases, and ancestry and paternity tests. It also markets age reversing creams and lotions.

INOL primarily serves healthcare providers, including physicians, hospitals, and outpatient facilities, as well as to individuals with a direct need for the solutions.

INOL Has Bright Future in Exploding DNA Testing Industry

INOL is very well placed in a very dynamic industry with demand running high across all its sub-sectors.

DNA testing represents a revolution postponed, perhaps, but one that is now clearly under way. After years of glowing predictions that didn’t immediately translate into change in clinical diagnostics, DNA testing has emerged fully from research into clinical practice, and is now one of the fastest growing segments of the diagnostics market.

Molecular tests are now used to diagnose disease and disease susceptibility, in prenatal genetic assessments, in tissue typing for organ transplantation, and to screen for inherited diseases.

Instrumentation now automates many of the sample-preparation and assay steps that were formerly labour-intensive. New tests are being launched all the time and many more are in development. The result is that molecular testing is now used in many areas of healthcare including: cardiology, oncology, infectious diseases, and inherited diseases and disorders.

Total sales of forensic products and services were nearly $10.1B in 2010 and that sales will grow at a 9.4% compound annual growth rate (CAGR) through 2016 to more than $17B.

Apart from computer forensics and forensics accounting, the largest segments of the forensics market are DNA testing and fingerprinting/biometrics.  DNA testing is expected to increase at a compound annual growth rate (CAGR) of 11.6%, from an approximate $1.3B at present to more than $2.3B by 2016.

Fingerprinting/biometrics are forecast to expand at a compound annual growth rate (CAGR) of9.8% during the same forecast period, rising to nearly $1.6B by 2016 from nearly $1B projected for 2011.

Recent Developments

Nick Plessas Joins Inolife Technologies, Inc. Executive Team as V.P. of Business Development

Inolife Technologies, Inc. (INOL), a diversified service-based healthcare and environmental product developer and marketer is pleased to announce the company has hired Mr. Nick Plessas as its V.P. of Business Development.

The company's CEO, Mr. Gary Berthold, states, "The addition of Mr. Plessas to the management team is important and is in keeping with its execution of the growth strategy. Mr. Plessas brings more than 25 years of experience in developing and marketing environmental solutions to the commercial and retail markets."

With strong expansion and development plans in place for 2013-2014, the Company has recruited Mr. Plessas to serve as a senior member of the management team to lead the areas of retail business development and new ventures.

Mr. Plessas will be responsible to research, identify, analyze and recommend specific business opportunities for the profitable growth in the retail sector, including identifying alliance partners, joint ventures, acquisitions and mergers.

Since having completed the curriculum of Masters Environmental Studies (M.E.S) program in 1980, Mr. Plessas has pioneered many leading edge, safe, effective and sustainable products by applying dynamic chemistry and nano-technology. With over 10 years of international experience, he possesses a strong understanding of customer and market dynamics and requirements.

Mr. Plessas' immediate focus will be centered on the all-natural skin care line for women and men's healthcare products. Inolife will combine patented compounds with all natural ingredients providing a healthcare and skincare product line with Anti-Aging beneficial properties.

INOL’s ambitious push towards expansion is good thing in every way. With so much growth potential untapped in the lucrative DNA testing space, rapidity of action is crucial to unlocking the most benefits from this explosive industry.

INOL is a play that is poised to make major moves northward.

I will be following up with my technical analysis very shortly. Get Ready For INOL and start your research now.

For information on INOL visit: http://www.inol.info/

Sincerely,

Alexander.

DISCLAIMER

Penny Stocks VIP

1000 N West Street, Suite 1200, Wilmington, DE, 19801